Blood Res.  2023 Dec;58(4):201-207. 10.5045/br.2023.2023174.

The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study

• Parvizi M
• Moghaddam MD
• Nazari S
• Ashraf H
• Aghdam MK

• KMID: 2550198
• DOI: http://doi.org/10.5045/br.2023.2023174

Abstract

Background
Oxidative stress due to iron accumulation in patients with beta-thalassemia major (BTM) causes complications such as tissue damage and destruction. This study aimed to assess the association between the serum prooxidant/antioxidant balance (PAB) and blood parameters in patients with BTM.
Methods
This cross-sectional study included 92 patients with BTM. In this study, PAB was measured using an enzyme-linked immunosorbent assay (ELISA). Serum ferritin, blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), thyroid-stimulating hormone (TSH), total cholesterol (TC), triglyceride (TG), complete blood cell count (CBC), and history of blood transfusion were recorded. The association of the blood parameters was assessed across the tertiles (T) of serum PAB (highest T vs. lowest T).
Results
The results showed that high serum ferritin was directly associated with serum PAB [odds ratio (OR), 12.80; 95% confidence interval (CI), 2.98‒54.91; T3 vs. T1]. Also, direct associations were found for high TC (OR, 4.97; 95% CI, 1.42‒17.32; T3 vs. T1), high ALT (OR, 4.95; 95% CI, 1.33‒18.46; T3 vs. T1) and high TSH (OR, 3.78; 95% CI, 1.10‒13.02; T3 vs. T1).
Conclusion
The findings of the present study showed that serum PAB levels were directly associated with ferritin, ALT, TC, and TSH levels. This indicates that improvements in blood parameters, especially ferritin and TSH levels, occur by ameliorating oxidative stress in patients with BTM.

Keyword

Beta-thalassemia; Antioxidants; Oxidants; Oxidative stress

Figure

• 

  Fig. 1 An illustration for measurement of the serum PAB (A) and its basis (B).Abbreviations: HCL, hydrochloride; OD, optical density; PAB, pro-oxidant antioxidant balance; TMB, tetrame-thylbenzidine. Abbreviations: HCL, hydrochloride; OD, optical density; PAB, pro-oxidant antioxidant balance; TMB, tetramethylbenzidine.

Reference

1. Galanello R, Origa R. 2010; Beta-thalassemia. Orphanet J Rare Dis. 5:11. DOI: 10.1186/1750-1172-5-11. PMID: 20492708. PMCID: PMC2893117. PMID: 6ab50d8294be49f4885c1beebdf25dfc.

2. Mirmomen S, Alavian SM, Hajarizadeh B, et al. 2006; Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 9:319–23. PMID: 17061602.

3. Moayeri H, Oloomi Z. 2006; Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med. 9:329–34. PMID: 17061604.

4. Mohammadi Z, Sharif Zak M, Seidi K, Barati M, Akbarzadeh A, Zarghami N. 2017; The effect of chrysin loaded PLGA-PEG on metalloproteinase gene expression in mouse 4T1 tumor model. Drug Res (Stuttg). 67:211–6. DOI: 10.1055/s-0042-122136. PMID: 28166590.

5. Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. 2012; Prevalence of anti HCV infection in patients with Beta-thalassemia in Isfahan-Iran. Int J Prev Med. 3(Suppl 1):S118–23. PMID: 22826753.

6. Adil A, Sobani ZA, Jabbar A, Adil SN, Awan S. 2012; Endocrine complications in patients of beta thalassemia major in a tertiary care hospital in Pakistan. J Pak Med Assoc. 62:307–10. DOI: 10.1530/endoabs.90.ep661.

7. Charafeddine K, Isma'eel H, Charafeddine M, et al. 2008; Survival and complications of beta-thalassemia in Lebanon: a decade's experience of centralized care. Acta Haematol. 120:112–6. DOI: 10.1159/000171088. PMID: 19001806.

8. Nemtsas P, Arnaoutoglou M, Perifanis V, Koutsouraki E, Orologas A. 2015; Neurological complications of beta-thalassemia. Ann Hematol. 94:1261–5. DOI: 10.1007/s00277-015-2378-z. PMID: 25903043.

9. Ghone RA, Kumbar KM, Suryakar AN, Katkam RV, Joshi NG. 2008; Oxidative stress and disturbance in antioxidant balance in beta thalassemia major. Indian J Clin Biochem. 23:337–40. DOI: 10.1007/s12291-008-0074-7. PMID: 23105782. PMCID: PMC3453139.

10. Shazia Q, Mohammad ZH, Rahman T, Shekhar HU. 2012; Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in Beta thalassemia major patients: a review of the literature. Anemia. 2012:270923. DOI: 10.1155/2012/270923. PMID: 22645668. PMCID: PMC3357501. PMID: 9ef15484aadb4b5bbf361d9909e24067.

11. Barati M, Jabbari M, Navekar R, et al. 2020; Collagen supplementation for skin health: a mechanistic systematic review. J Cosmet Dermatol. 19:2820–9. DOI: 10.1111/jocd.13435. PMID: 32436266.

12. Salehi-Sahlabadi A, Teymoori F, Jabbari M, et al. 2021; Dietary polyphenols and the odds of non-alcoholic fatty liver disease: a case-control study. Clin Nutr ESPEN. 41:429–35. DOI: 10.1016/j.clnesp.2020.09.028. PMID: 33487302.

13. Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. 2007; A novel assay for the evaluation of the prooxidant- antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 40:248–54. DOI: 10.1016/j.clinbiochem.2006.10.017. PMID: 17196578.

14. Fibach E, Dana M. 2019; Oxidative stress in β-thalassemia. Mol Diagn Ther. 23:245–61. DOI: 10.1007/s40291-018-0373-5. PMID: 30484264.

15. Ondei Lde S, Estevão Ida F, Rocha MI, et al. 2013; Oxidative stress and antioxidant status in beta-thalassemia heterozygotes. Rev Bras Hematol Hemoter. 35:409–13. DOI: 10.5581/1516-8484.20130122. PMID: 24478607. PMCID: PMC3905823. PMID: 24da0bb3274541e6859eed6c4b710ba5.

16. Salehi-Sahlabadi A, Mokari A, Elhamkia M, Farahmand F, Jabbari M, Hekmatdost A. 2020; Dietary total antioxidant capacity and risk of non-alcoholic fatty liver disease: a case-control study. J Res Health Sci. 20:e00486. DOI: 10.34172/jrhs.2020.18. PMID: 33169718. PMCID: PMC7585767.

17. Guzelcicek A, Cakirca G, Erel O, Solmaz A. 2019; Assessment of thiol/disulfide balance as an oxidative stress marker in children with β-thalassemia major. Pak J Med Sci. 35:161–5. DOI: 10.12669/pjms.35.1.307. PMID: 30881416. PMCID: PMC6408658.

18. Ehteram H, Bavarsad MS, Mokhtari M, et al. 2014; Prooxidant- antioxidant balance and hs-CRP in patients with beta-thalassemia major. Clin Lab. 60:207–15. DOI: 10.7754/Clin.Lab.2013.130132. PMID: 24660532.

19. Ghorban K, Shanaki M, Mobarra N, et al. 2016; Apolipoproteins A1, B, and other prognostic biochemical cardiovascular risk factors in patients with beta-thalassemia major. Hematology. 21:113–20. DOI: 10.1179/1607845415Y.0000000016. PMID: 25913481.

20. Ghahremanlu E, Banihashem A, Saber H, et al. 2013; Increased serum heat shock protein 27 antibody titers and prooxidant-antioxidant balance in patients with beta-thalassemia major. Acta Haematol. 129:1–9. DOI: 10.1159/000339502. PMID: 22964881.

21. Lai ME, Vacquer S, Carta MP, et al. 2011; Evidence for a proatherogenic biochemical phenotype in beta thalassemia minor and intermedia. Acta Haematol. 126:87–94. DOI: 10.1159/000327252. PMID: 21576933.

22. Upadya SH, Rukmini MS, Sundararajan S, Baliga BS, Kamath N. 2018; Thyroid function in chronically transfused children with beta thalassemia major: a cross-sectional hospital based study. Int J Pediatr. 2018:9071213. DOI: 10.1155/2018/9071213. PMID: 30305822. PMCID: PMC6165584. PMID: 8746c74a89ff4b6e8561b548fe6eef84.

23. Benli AR, Yildiz SS, Cikrikcioglu MA. 2017; An evaluation of thyroid autoimmunity in patients with beta thalassemia minor: a case-control study. Pak J Med Sci. 33:1106–11. DOI: 10.12669/pjms.335.13210. PMID: 29142547. PMCID: PMC5673716.

24. Eshragi P, Tamaddoni A, Zarifi K, Mohammadhasani A, Aminzadeh M. 2011; Thyroid function in major thalassemia patients: is it related to height and chelation therapy? Caspian J Intern Med. 2:189–93. PMID: 24024013. PMCID: PMC3766932.

25. Chakrabarti SK, Ghosh S, Banerjee S, Mukherjee S, Chowdhury S. 2016; Oxidative stress in hypothyroid patients and the role of antioxidant supplementation. Indian J Endocrinol Metab. 20:674–8. DOI: 10.4103/2230-8210.190555. PMID: 27730079. PMCID: PMC5040049. PMID: ce8b8c813fee44aa82d5d482a555893d.

26. Mancini A, Di Segni C, Raimondo S, et al. 2016; Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm. 2016:6757154. DOI: 10.1155/2016/6757154. PMID: 27051079. PMCID: PMC4802023. PMID: 5e7c0c75c8d042b29e60b154dde25a56.

27. Soliman A, Yassin M, Al Yafei F, et al. 2014; Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy. Mediterr J Hematol Infect Dis. 6:e2014025. DOI: 10.4084/mjhid.2014.025. PMID: 24803998. PMCID: PMC4010606. PMID: d7a8e6cecdb6400abe05f6b3f5a103b1.

28. Al-Moshary M, Imtiaz N, Al-Mussaed E, Khan A, Ahmad S, Albqami S. 2020; Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion- dependent thalassemia patients. Cureus. 12:e7574. DOI: 10.7759/cureus.7574. PMID: 32391223. PMCID: PMC7205361.